Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism
Luo, S.; Zhang, J.; Kreutzberger, A. J. B.; Eaton, A.; Edwards, R. J.; Jing, C.; Dai, H.-Q.; Sempowski, G. D.; Cronin, K.; Parks, R.; Ye, A. Y.; Mansouri, K.; Barr, M.; Pishesha, N.; Williams, A. C.; Francisco, L. V.; Saminathan, A.; Peng, H.; Batra, H.; Bellusci, L.; Khurana, S.; Alam, S. M.; Montefiori, D. C.; Saunders, K. O.; Tian, M.; Ploegh, H.; Kirchhausen, T.; Chen, B.; Haynes, B. F.; Alt, F. W.
Show abstract
SARS-CoV-2 Omicron variants have generated a world-wide health crisis due to resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of antibodies induced by vaccination. Here, we describe the SARS-CoV-2 neutralizing SP1-77 antibody that was generated from a humanized mouse model with a single human VH1-2 and V{kappa}1-33-associated with immensely diverse complementarity-determining-region-3 (CDR3) sequences. SP1-77 potently and broadly neutralizes SARS-CoV-2 variants of concern and binds the SARS-CoV-2 spike protein receptor-binding-domain (RBD) via a novel-CDR3-based mode. SP1-77 does not block RBD-binding to the ACE2-receptor or endocytosis step of viral entry, but rather blocks membrane fusion. Our findings provide the first mechanistic insight into how a non-ACE2 blocking antibody potently neutralizes SARS-CoV-2, which may inform strategies for designing vaccines that robustly neutralize current and future SARS-CoV-2 variants.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Broadly neutralizing antibodies target the coronavirus fusion peptide 98%
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants 98%
- Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants 98%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses 97%
- Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals 97%
- One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening 97%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.